RT-3 20mg Vial
High purity research peptide
$70.00$50.00
Key Potential Benefits (From Clinical Trial Data)
Exceptional Weight Loss
Achieves some of the highest reported reductions in late-stage obesity trials.
In Phase 2: Up to ~24.2% mean body weight loss at 48 weeks (12 mg dose) in people with obesity/overweight.
In Phase 3 TRIUMPH-4 (obesity + knee osteoarthritis, no diabetes): Up to 28.7% average loss (~71.2 lbs / ~32.3 kg) at 68 weeks on the 12 mg dose (efficacy estimand; among completers). Intent-to-treat analyses showed ~23-24% loss.
High proportions achieve major thresholds (e.g., >20-25% loss common at higher doses).
Greater fat mass reduction with relative preservation of lean mass compared to some predecessors.
Improved Cardiometabolic Risk Factors
Reduces markers like non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP, inflammation).
Lowers systolic blood pressure (up to ~14 mmHg at highest dose in TRIUMPH-4).
Improves fasting glucose, insulin levels, and overall glycemic control (especially beneficial in type 2 diabetes or prediabetes).
Ongoing TRIUMPH-Outcomes trial evaluates hard cardiovascular endpoints (MACE) and kidney outcomes in high-risk populations.
Relief from Obesity-Related Complications
Substantial pain reduction and improved physical function in knee osteoarthritis (TRIUMPH-4): Up to ~75.8% reduction in WOMAC pain score; many achieved complete pain resolution (12-14% vs. ~4% on placebo).
Potential for benefits in other weight-related issues (e.g., chronic low back pain in ongoing trials, obstructive sleep apnea, mobility/energy levels).
Qualitative reports from Phase 2 participants: Enhanced eating control, reduced hunger/frequency, better mood/confidence, increased activity/social engagement, and clothing size reductions.
Other Emerging Benefits
Enhanced energy expenditure (glucagon component may boost metabolism beyond appetite effects alone).
Broader metabolic improvements (e.g., liver fat reduction implied in related mechanisms).
Potential for superior outcomes vs. dual agonists in direct head-to-heads (ongoing trials compare to tirzepatide).
These benefits generally occur alongside diet/exercise and stem from synergistic hormone actions: GLP-1/GIP for satiety/insulin, glucagon for fat oxidation/energy use.
